Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study

Trial Profile

Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2018 Status changed from recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 07 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top